Lynne Neagle raises a very important point, an opportunity for me to update on the All Wales Medicines Strategy Group consideration. They’re finalising, I understand, the scope and timelines for appraising Avastin. And, of course, this is a situation where we know that there is opportunity to make applications through the individual patient funding requests process, on patients’ behalf. But I think the overall appraisal, of course, is what is sought, and that will be very shortly forthcoming.